U.S. FDA panel backs approval of Novo Nordisk diabetes drug

WASHINGTON (Reuters) - Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.